1. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt
Results for "

WNT

" in MedChemExpress (MCE) Product Catalog:

449

Inhibitors & Agonists

9

Screening Libraries

7

Fluorescent Dyes

9

Biochemical Assay Reagents

28

Peptides

3

MCE Kits

6

Inhibitory Antibodies

76

Natural
Products

15

Recombinant Proteins

4

Isotope-Labeled Compounds

30

Antibodies

43

Oligonucleotides

6

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15659
    Wnt-C59
    35+ Cited Publications

    C59

    Porcupine Wnt Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Wnt-C59 (C59) is a highly potent and oral porcupine (PORCN) inhibitor with an IC50 of 74 pM.
    Wnt-C59
  • HY-12238
    IWR-1
    60+ Cited Publications

    endo-IWR 1; IWR-1-endo

    Organoid Wnt Inflammation/Immunology Cancer
    IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC50 = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis .
    IWR-1
  • HY-17545
    LGK974
    40+ Cited Publications

    WNT974

    Porcupine Cancer
    LGK974 (WNT974) is an orally bioavailable and specific Porcupine (PORCN) inhibitor with an IC50 of 0.1 nM .
    LGK974
  • HY-120697
    MSAB
    45+ Cited Publications

    Wnt β-catenin Cancer
    MSAB is a potent and selective inhibitor of Wnt/β-catenin signaling. MSAB binds to β-catenin and promotes its degradation, and specifically downregulates Wnt/β-catenin target genes. MSAB exhibits potent anti-tumor effects selectively on Wnt-dependent cancer cells .
    MSAB
  • HY-153855

    RXC004

    Wnt Acyltransferase Porcupine Cancer
    Zamaporvint (RXC004) is an orally active and selective inhibitor of Wnt. Zamaporvint targete membrane-bound o-acyltransferase Porcupine and inhibited Wnt ligand palmitoylation, secretion, and pathway activation. Zamaporvint displays a favorable pharmacokinetic profile and shows potent antiproliferative effects in Wnt ligand-dependent colorectal and pancreatic cell lines. Zamaporvint possesses multiple antitumor mechanisms and can be used in cancer research .
    Zamaporvint
  • HY-151520

    Wnt Cancer
    Wnt/β-catenin agonist 4 (Derivative 83) is an agonist of Wnt that activates Wnt/β-catenin signal transmission .
    Wnt/β-catenin agonist 4
  • HY-12762
    QS11
    2 Publications Verification

    β-catenin Wnt Arf Family GTPase Cancer
    QS11 is an inhibitor of ARFGAP1 (ADP-ribosylation factor GTPase-activating protein 1), with an EC50 of 1.5 μM. QS11 activates Wnt/β-catenin signaling through an effect on protein trafficking. QS11 inhibits migration of ARFGAP overexpressing breast cancer cells .
    QS11
  • HY-18285

    Wnt Casein Kinase ERK CDK Cancer
    Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. Longdaysin inhibits CK1α, CK1δ, CDK7, and ERK2 with IC50s of  5.6 µM, 8.8 µM, 29 µM, and 52 µM, respectively .
    Longdaysin
  • HY-N10790

    Wnt c-Myc Notch Cancer
    RA-V is a cyclic hexapeptide. RA-V has activity against Wnt, Myc and Notch with IC50 values of 50, 75, and 93 ng/mL, respectively. RA-V can be used for the research of cancer-related signaling pathways .
    RA-V
  • HY-135516
    Dalosirvat
    2 Publications Verification

    SM-04554; WNT pathway activator 1

    Wnt Neurological Disease Metabolic Disease Cancer
    Dalosirvat (SM-04554) is a potent Wnt activator with an EC50s of 28-29 nM. Dalosirvat can be used in the study of cancer .
    Dalosirvat
  • HY-15659G

    C59

    Porcupine Wnt Cancer
    Wnt-C59 (C59) GMP is a GMP grade Wnt-C59 (HY-15659). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Wnt-C59 (C59) is a highly potent and oral porcupine (PORCN) inhibitor with an IC50 of 74 pM.
    Wnt-C59
  • HY-15825
    IWP L6
    4 Publications Verification

    Porcn Inhibitor III

    Porcupine Cancer
    IWP L6 (Porcn Inhibitor III) is a Porcupine (Porcn) inhibitor with an EC50 of 0.5 nM. IWP L6 disrupts well-established Wnt-dependent developmental processes of embryonic and juvenile zebrafish .
    IWP L6
  • HY-117666
    NSC668036
    3 Publications Verification

    Wnt Inflammation/Immunology
    NSC668036 is a Dishevelled (Dvl) PDZ domain inhibitor with a Kd of 237 μM. NSC668036 blocks Wnt signaling by interrupting the Frizzled-Dvl interaction .
    NSC668036
  • HY-172920

    Wnt β-catenin EGFR ERK COX Akt GSK-3 c-Myc Apoptosis Interleukin Related JNK Inflammation/Immunology Cancer
    Wnt/β-catenin-IN-6 is an orally active Wnt/β-catenin pathway inhibitor. Wnt/β-catenin-IN-6 blocks the AKT/GSK-3β/β-catenin signaling pathway, leading to reduced expression of Wnt target genes (c-Myc, c-Jun). Wnt/β-catenin-IN-6 reduces COX2 expression and IL-8 levels, highlighting its dual anti-inflammatory and antitumor effects. Wnt/β-catenin-IN-6 can induce apoptosis. Wnt/β-catenin-IN-6 serves as a tool for non-small cell lung cancer (NSCLC) research .
    Wnt/β-catenin-IN-6
  • HY-D1474

    Wnt Cancer
    WNT7A-IN-1 sodium (1365-0109), a WNT7A inhibitor, disrupts the protein-protein interaction between WNT7A and its receptor FZD5, resulting in the upregulation of MHC-I expression. WNT7A-IN-1 sodium significantly increases the expression of MHC-I and p-p65,while concurrently reducing the expression of active β-catenin . WNT7A-IN-1 sodium (compound F) is also a photographic sensitizer in the green spectral region .
    WNT7A-IN-1 sodium
  • HY-100536

    Wnt Cancer
    IWP-3 is an potent inhibitor of Wnt production with an IC50 of 40 nM. IWP-3 inhibits Porcupine (Porcn) function thereby blocking palmitoylation of Wnt proteins. IWP-3 inhibits CK1γ3 and CK1ε only moderately and does not inhibit CK1α .
    IWP-3
  • HY-142689

    Carboxylesterase (CES) Wnt Cancer
    Carboxylesterase-IN-3 (compound 4y) is a potent inhibitor of Carboxylesterase Notum with an IC50 less than or equal to 10 nM. Notum is a negative regulator of Wnt signaling acting through the hydrolysis of a palmitoleoylate ester, which is required for Wnt activity. Carboxylesterase-IN-3 has the potential for the research of cancer disease .
    Carboxylesterase-IN-3
  • HY-116553

    Wnt β-catenin Cancer
    FzM1 is a negative allosteric modulator (NAM) of Frizzled receptor FZD4. FzM1 reduces WNT5A-dependent WNT responsive element (WRE) activity (log EC50inh=?6.2). FzM1 binds to an allosteric binding site located in intracellular loop 3 (ICL3) of FZD4 and alters the conformation of the receptor, ultimately inhibiting the WNT/β-catenin cascade .
    FzM1
  • HY-100408

    Wnt Porcupine Cardiovascular Disease Cancer
    GNF-6231 is a porcupine (IC50= 0.8 nM), Pron, and endoplasmic reticulum protein inhibitor with oral activity. GNF-6231 has anticancer activity. GNF-6231 can prevent the activation of the Wnt pathway by blocking the secretion of all Wnt ligands. GNF-6231 can be used in the study of myocardial infarction .
    GNF-6231
  • HY-170411

    Wnt Cancer
    WNT7A-IN-1 (1365-0109), a WNT7A inhibitor, disrupts the protein-protein interaction between WNT7A and its receptor FZD5, resulting in the upregulation of MHC-I expression. WNT7A-IN-1 significantly increases the expression of MHC-I and p-p65,while concurrently reducing the expression of active β-catenin. WNT7A-IN-1 (compound F) is also a photographic sensitizer in the green spectral region .
    WNT7A-IN-1
  • HY-141873
    Wnt/β-catenin agonist 2
    1 Publications Verification

    Wnt β-catenin Others
    Wnt/β-catenin agonist 2 is a potent Wnt agonist. Wnt/β-catenin agonist 2 activates Wnt/β-catenin signaling and can be used in the research of diseases related to the signal transduction . (From patent WO2007078113A1, compound 39)
    Wnt/β-catenin agonist 2
  • HY-148055

    Wnt β-catenin Cardiovascular Disease
    Wnt/β-catenin agonist 3 (compound 98) is a Wnt/β-catenin signalling pathway agonist. Wnt/β-catenin agonist 3 can be used for the research of osteoporosis .
    Wnt/β-catenin agonist 3
  • HY-114321
    Wnt/β-catenin agonist 1
    5+ Cited Publications

    Wnt Cancer
    Wnt/β-catenin agonist 1 (compound 3f) is a Wnt/β-catenin signalling pathway agonist, with an EC50 of 0.27 μM .
    Wnt/β-catenin agonist 1
  • HY-136541
    YB-0158
    2 Publications Verification

    WNT pathway inhibitor 2

    Wnt Apoptosis Cancer
    YB-0158 (Wnt pathway inhibitor 2) is a reverse-turn peptidomimetic and a potent colorectal cancer stem cell (CSC) targeting agent. YB-0158 disrupts Sam68-Src interactions and induces apoptosis in CRC cells. Anti-cancer activities .
    YB-0158
  • HY-153750

    Wnt Cancer
    Wnt pathway inhibitor 3 is a potent wnt inhibitor with an IC50 value of 45 nM. Wnt pathway inhibitor 3 shows antiproliferative activity .
    Wnt pathway inhibitor 3
  • HY-160709

    Wnt β-catenin Cancer
    Wnt/β-catenin-IN-2 (Compound 3235-0367) is a Wnt/β-catenin signaling pathway inhibitor, with IC50 and KD values of 7.1 and 2.5 μM, respectively. Wnt/β-catenin-IN-2 can be used for the research of cancer .
    Wnt/β-catenin-IN-2
  • HY-15659R

    C59 (Standard)

    Porcupine Wnt Reference Standards Cancer
    Wnt-C59 (Standard) is the analytical standard of Wnt-C59. This product is intended for research and analytical applications. Wnt-C59 (C59) is a highly potent and oral porcupine (PORCN) inhibitor with an IC50 of 74 pM.
    Wnt-C59 (Standard)
  • HY-P10392B

    β-catenin Wnt Cancer
    aStAx-35R TFA, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R TFA inhibits competitively the binding of β-catenin to TCF4. aStAx-35R TFA selectively induces growth inhibition of Wnt-dependent cancer cells .
    aStAx-35R TFA
  • HY-153580

    Wnt Cancer
    WIC1 is a potent Wnt inhibitor. WIC1 can be used for the research of cancer .
    WIC1
  • HY-10860

    sFRP-1 Wnt β-catenin Metabolic Disease
    WAY-362692 is a secreted frizzled-related protein (sFRP-1) inhibitor (IC50 of 0.02 μM), targeting the netrin domain of sFRP-1. WAY-362692 can competitively inhibit the interaction between sFRP-1 and Wnt proteins, and activate the Wnt/β-catenin signaling pathway (EC50 = 0.03 μM). WAY-362692 can activate osteoblasts and promote bone remodeling. WAY-362692 can be used for the research of metabolic disease, such as osteoporosis .
    WAY-362692
  • HY-136073

    Wnt Cancer
    Wnt pathway activator 2 (compound 2) is a potent Wnt activator with an EC50 of 13 nM .
    Wnt pathway activator 2
  • HY-173482

    Wnt β-catenin Cancer
    TFAP4/Wnt/β-catenin-IN-1 (Compound A61) is an orally active TFAP4/Wnt/β-catenin inhibitor. TFAP4/Wnt/β-catenin-IN-1 has significant anticancer activity against a variety of cancer cells (such as gastric cancer, lung cancer, breast cancer, etc.), and has the strongest anticancer activity against MGC-803 gastric cancer cells (IC50: 3.92 μM). TFAP4/Wnt/β-catenin-IN-1 induces apoptosis and cell cycle arrest (S phase) in cancer cells by inhibiting the TFAP4/Wnt/β-catenin signaling pathway. TFAP4/Wnt/β-catenin-IN-1 can be used in the study of gastric cancer .
    TFAP4/Wnt/β-catenin-IN-1
  • HY-P10164

    Wnt Cancer
    Pen-N3 is a PDZ peptide. Pen-N3 inhibits Wnt/b-catenin signaling by recognizing dishevelled protein .
    Pen-N3
  • HY-142688

    Carboxylesterase (CES) Wnt Cancer
    Carboxylesterase-IN-2 (compound 4u) is a potent inhibitor of Carboxylesterase Notum with an IC50 less than or equal to 10 nM. Notum is a negative regulator of Wnt signaling acting through the hydrolysis of a palmitoleoylate ester, which is required for Wnt activity. Carboxylesterase-IN-2 has the potential for the research of cancer disease .
    Carboxylesterase-IN-2
  • HY-155391

    Carbonic Anhydrase P-glycoprotein Wnt β-catenin Cancer
    hCA/Wnt/β-catenin-IN-1 (Compd 15) is an inhibitor of hCA (Ki: 33.6, 24.1, 6.8 nM for hCA II, hCA IX, hCA XII). hCA/Wnt/β-catenin-IN-1 reduces P-gp activity. hCA/Wnt/β-catenin-IN-1 also inhibits Wnt/β-catenin signaling pathway. hCA/Wnt/β-catenin-IN-1 inhibits cancer cell viability, including the NCI/ADR-RES DOX-resistant cell line .
    hCA/Wnt/β-catenin-IN-1
  • HY-RS15828

    Small Interfering RNA (siRNA) Others

    WNT10A Human Pre-designed siRNA Set A contains three designed siRNAs for WNT10A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    WNT10A Human Pre-designed siRNA Set A
    WNT10A Human Pre-designed siRNA Set A
  • HY-RS15837

    Small Interfering RNA (siRNA) Others

    WNT5A Human Pre-designed siRNA Set A contains three designed siRNAs for WNT5A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    WNT5A Human Pre-designed siRNA Set A
    WNT5A Human Pre-designed siRNA Set A
  • HY-111460

    NC 043

    Wnt Cancer
    15-Oxospiramilactone is a diterpene derivative. 15-Oxospiramilactone can inhibit Wnt/β-catenin signaling and tumorigenesis of colon cancer cells .
    15-Oxospiramilactone
  • HY-173489

    Wnt β-catenin Cancer
    Wnt/β-catenin-IN-5 (compound 19T) is a Wnt/β-catenin signaling pathway inhibitor. Wnt/β-catenin-IN-5 inhibits HCT 116, SW480, and A549 cells activity with IC50s of 3.05, 3.27 and 34.91 μM, respectively .
    Wnt/β-catenin-IN-5
  • HY-P10392

    β-catenin Wnt Cancer
    aStAx-35R, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R inhibits competitively the binding of β-catenin to TCF4. aStAx-35R selectively induces growth inhibition of Wnt-dependent cancer cells .
    aStAx-35R
  • HY-49597

    Wnt β-catenin Cancer
    Pin1 modulator 1 (compound IIb-219) is a modulator that specifically targets β-Catenin and inhibits the Wnt pathway. Pin1 modulator 1 can be used in the study of Wnt-mediated related diseases, such as cancer .
    Pin1 modulator 1
  • HY-145686

    Wnt Nuclear Factor of activated T Cells (NFAT) Inflammation/Immunology
    AV023 is a potent inhibitor of ANKRD22. AV023 promotes the expansion of gastrointestinal mucosal epithelial stem cells and indirectly activates the Wnt classical pathway, which helps the recovery of damaged gastrointestinal mucosal tissues in the body (extracted from patent CN111205231B) .
    AV023
  • HY-108516

    Wnt PARP Cancer
    TC-E 5001 is an inhibitor of Wnt pathway that inhibits tankyrase 1/2 (TNKS1/2) via novel adenosine pocket binding, with Kds of 79 nM and 28 nM, respectively. TC-E 5001 also inhibits Axin2 and STF, with IC50s of 0.709 μM and 0.215 μM, respectively .
    TC-E 5001
  • HY-133179

    Wnt Metabolic Disease
    Wnt/β-catenin-IN-4 (compound YW1159) is a potent Wnt/β-catenin inhibitor .
    Wnt/β-catenin-IN-4
  • HY-157990

    Wnt β-catenin Cancer
    Wnt/β-catenin-in-1 (compounds 17) is a Wnt/β-catenin signaling pathway inhibitor. Wnt/β-catenin-IN-1 can induce apoptosis of colon cancer cells, has broad-spectrum anticancer activity, and can be used for the reseach of a variety of solid tumors .
    Wnt/β-catenin-IN-1
  • HY-148055A

    Wnt β-catenin Others
    Wnt/β-catenin agonist 3 hydrochloride is a Wnt/β-catenin signalling pathway agonist. Wnt/β-catenin agonist 3 (compound 98) can be used for the research of osteoporosis .
    Wnt/β-catenin agonist 3 hydrochloride
  • HY-169730

    Wnt Cancer
    Wnt pathway inhibitor 5 (Compound 28) is wnt pathway inhibitor, with an IC50 value of < 0.003 μΜ. Wnt pathway inhibitor 5 inhibits many cancers, including ovarian teratocarcinoma cancer, breast cancer, osteosarcoma, head and neck squamous carcinoma .
    Wnt pathway inhibitor 5
  • HY-158210

    Wnt β-catenin MDM-2/p53 Cancer
    Wnt/β-catenin-IN-3 (compound 17) is a Wnt/β-catenin inhibitor with low micromolarGI50s against various cancer cells. Wnt/β-catenin-IN-3triggers G2/M cell cycle arrest though activation of p53-p21 pathway as well as intrinsic and extrinsic apoptotic death of colon cancer cells .
    Wnt/β-catenin-IN-3
  • HY-RS23648

    Small Interfering RNA (siRNA) Others

    Wnt4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Wnt4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Wnt4 Rat Pre-designed siRNA Set A
    Wnt4 Rat Pre-designed siRNA Set A
  • HY-RS15839

    Small Interfering RNA (siRNA) Others

    WNT6 Human Pre-designed siRNA Set A contains three designed siRNAs for WNT6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    WNT6 Human Pre-designed siRNA Set A
    WNT6 Human Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: